Zum Inhalt springen
Global sound
Dr. John Campbell

Dr. John Campbell

New constructive ivermectin evidence

· 27 Min.

Shownotes

A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2

https://www.mdpi.com/1999-4923/17/9/1205

People who took one small oral dose of ivermectin after exposure,

took longer to test positive and had more time alive and free of symptoms.

Multiple reports from in vitro infectious models document Ivermectin’s antiviral properties

https://pmc.ncbi.nlm.nih.gov/articles/PMC7564151/pdf/cells-09-02100.pdf

Ivermectin has broad-spectrum antiviral activity.

Randomised, double-blind, placebo-controlled

Single oral dose of Ivermectin as prophylaxis for SARS-CoV-2

Trial to evaluate the effectiveness of a single oral low dose of Ivermectin

Ability to prevent SARS-CoV-2 infection?

Ability to reduce symptoms if infection did occur?

Methods

Asymptomatic community-dwelling adults

Enrolled within 72 h of close contact with a case of SARS-CoV-2.

Single oral 200 µg/kg dose of Ivermectin or placebo.

65Kg woman given 13mg

80Kg man given 16mg

The primary outcome

Conversion to a positive PCR or RAT test within 14 days of close contact.

Secondary outcomes

(for those who tested positive)

Days alive free of symptoms in the 14 and 28 days following ivermectin

Days from close contact until a positive PCR or RAT

Results

N = 536 (86 met inclusion criteria and were randomised)

68 adhered and were included in the analysis.

Ivermectin arm

11/36 tested positive

Placebo arm

11/32 tested positive

So, ivermectin did not prevent people testing positive

Days from close contact until a positive PCR or RAT

Increased by 2.3 days in ivermectin group.

P = 0.033

So, ivermectin lengthened the incubation period

Viral load needed to precipitate clinical disease took longer to develop – indicating an antiviral effect.

Infection may have been prevented from primary contact, - indicating an antiviral effect.

Days alive free of symptoms

Increased by 2.5 days in ivermectin group.

P = 0.036

So ivermectin delayed onset of symptoms in people who tested positive

(Longer asymptomatic period)

Controlling included

Age, prior SARS-CoV-2 infection, body mass index, hypertension, lung disease

Conclusions

We did not demonstrate that a single oral low dose of Ivermectin administered to asymptomatic adults within 72 h of close contact with a case of
SARS-CoV-2 prevents conversion to a positive PCR or RAT.

(may have done with a larger sample size)

Amongst those who did convert to a positive PCR or RAT

Ivermectin significantly lengthened the time from close contact to conversion

Ivermectin increased the number of days alive free of symptoms

More details

Initiation of this trial in late 2021

Discovery in 1975

Massively used around the world

Nobel Prize in 2015

Very low incidence of serious adverse side effects

No instance of resistance reported in over 25 years.

Ivermectin can bind to and inhibit the nuclear transport roles of the host importin α (IMPα) protein,

which is…

Live, letzte Stunde: 13.101 Songs auf 6.643 Sendern in 143 Ländern

Entdecke die Welt über das Radio

Mehr zum Entdecken (9)

Etwas Schönes gehört? Speicher es oder öffne es direkt in Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
Milatina.caWeiterhören